Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701258 · ClinicalTrials.gov registry record · Phase 1
An Investigation of Early Life Stress and Depression
A Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT01701258 is a Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 153 participants.
The verdict
NCT01701258, a Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD). Hypotheses: The CSA/MDD participants will be characterized by (1) reduced reward responsiveness and prefrontal cortex activity, but increased cortisol levels, (2) reduced dopamine activity, and (3) reduced dopamine transporter binding. The over-arching purpose of the study is to (1) identify individuals at risk for psychopathology and maladaptive behavior, (2) prevent re-victimization, and (3) develop more targeted therapeutic interventions.
Interventions
- DRUG Placebo
- DRUG Amisulpride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701258
The ClinicalTrials.gov registry entry for NCT01701258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01701258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701258 about?
NCT01701258 is a clinical study titled "An Investigation of Early Life Stress and Depression". The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD). Hypotheses: The CSA/MDD participants will be characterized by (1) reduced reward r...
What is the current status of trial NCT01701258?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2013-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01701258?
The interventions under investigation include: Placebo (DRUG), Amisulpride (DRUG).
Who is sponsoring clinical trial NCT01701258?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.